AIM ImmunoTech develops therapies for cancers, viral diseases and immune disorders, led by its Ampligen treatment candidate. It last closed at $0.14 on Nov 17, down 0.07% on the day.
Only 1 firm rated AIM in the past 90 days, not enough for a consensus
Average 12-month target
$7.00
▲ 5032.0% upside
Based on 1 analyst who set a price target on AIM in the past 90 days. The average target is $7.00, with a high of $7.00 and a low of $7.00, compared with the last close of $0.14.
Low $7.00Avg $7.00High $7.00
Blue marker: last close $0.14
Highest target$7.00
Average target$7.00
Lowest target$7.00
Latest rating changes
Ascendiant CapitalTarget lowered
Aug 20Buy$9 → $7
Ascendiant CapitalMaintained
Jun 1Buy$9
Date
Firm
Action
Rating
Price target
Aug 20
Ascendiant Capital
Target lowered
Buy
$9 → $7
Jun 1
Ascendiant Capital
Maintained
Buy
$9
Loading…
Technical Analysis
AIM · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold
The stock is 14% below its 20 day and 30% below its 50 day average. It is 212% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 33), near oversold. The nearest support is the Pivot S1 at $0.13, and the nearest resistance the Pivot at $0.14.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 9.8%/day
Key levels
$1.8852 week high+1242.9%
$0.43200 day average+207.1%
$0.22100 day average+57.1%
$0.1850 day average+28.6%
$0.17Swing high (Oct 28)+21.4%
$0.1620 day average+14.3%
$0.14Pivot R1+0.0%
$0.14Pivot+0.0%
$0.14Last close
$0.13Pivot S1−7.1%
$0.1252 week low−14.3%
$0.12Swing low (Nov 10)−14.3%
Indicators
RSI (14)
32.92
Weak, oversold below 30
Neutral
MACD
-0.01
Below its signal line
Bearish
Stochastic
36.1
Middle of its range
Neutral
ADX (14)
40.1
Strong downtrend
Williams %R
-68.8
Oversold below −80, overbought above −20
Neutral
CCI (20)
-154.5
Oversold below −100, overbought above 100
Oversold
Rate of change
−15.6%
Change over 10 sessions
Bearish
ATR (14)
$0.01
Typical daily range, 9.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 85.4%/day
Key levels
$1.8852 week high+1242.9%
$0.43200 day average+207.1%
$0.22100 day average+57.1%
$0.1850 day average+28.6%
$0.17Swing high (Oct 28)+21.4%
$0.1620 day average+14.3%
$0.14Pivot R1+0.0%
$0.14Pivot+0.0%
$0.14Last close
$0.13Pivot S1−7.1%
$0.1252 week low−14.3%
$0.12Swing low (Nov 10)−14.3%
Indicators
RSI (14)
28.21
Oversold below 30
Oversold
MACD
-0.16
Above its signal line
Bullish
Stochastic
6.6
Near the bottom of its range
Oversold
ADX (14)
29.0
Trending up
Williams %R
-93.5
Oversold below −80, overbought above −20
Oversold
CCI (20)
-115.4
Oversold below −100, overbought above 100
Oversold
Rate of change
−38.5%
Change over 10 sessions
Bearish
ATR (14)
$0.12
Typical daily range, 85.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for AIM
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how AIM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow AIM usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How AIM has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AIM is in one of them and how their past AIM trades turned out.
AIM ImmunoTech is a biopharmaceutical company based in Ocala, Florida, that develops treatments for cancers, viral diseases and immune disorders. Its lead candidate, Ampligen, is an RNA molecule being studied mainly for pancreatic cancer, with other studies covering viral infections and fatigue after COVID-19. Ampligen is approved for sale in Argentina for severe chronic fatigue syndrome but has not been approved in the United States. The company also offers Alferon N Injection, an interferon product, and aims its therapies at patients with conditions where treatment options are limited.